The short answer: appetite comes back. For most people that means food noise returns, hunger increases, and without structure in place, weight tends to follow. None of that is a sign you did anything wrong — but it is worth preparing for.
Mounjaro (tirzepatide) works partly by acting on gut hormone signalling — slowing how quickly the stomach empties and influencing how the brain regulates hunger and fullness. Those effects taper off over a few weeks after your last dose as the drug clears.
What people typically notice, in roughly this order:
No — but it is common, and it's better to know that than be surprised by it.
Studies following people who discontinue GLP-1 and dual-agonist medications have generally found significant weight regain over the year that follows. This pattern is consistent enough that it should be treated as the default expectation rather than a worst case.
But "common" is not "inevitable," and the difference between the two is usually structure. Which brings us to the part that gets missed.
Here is the thing that rarely gets said clearly. While you were on Mounjaro, the medication was doing a very large amount of work: managing appetite, dampening cravings, making moderate eating feel effortless rather than effortful.
Whatever eating patterns you had during that time were built on top of that support. They didn't need to withstand real hunger, because there wasn't much. They were never tested.
Regain after medication isn't a lack of discipline — it's an unmanaged transition.
When the medication stops, those same patterns suddenly have to hold under conditions they were never built for. Most don't. That's a design problem, not a character one — and design problems can be solved.
The most useful period is the one while you're still on medication, or tapering — because appetite is still quiet, so building new habits is far easier. It's also the period people most reliably waste, precisely because nothing feels urgent yet.
Protein at every meal, adequate volume, consistent timing. Establishing this while appetite is suppressed means it's a routine by the time hunger returns, rather than something you're trying to start in the middle of a hard week.
Weight lost on tirzepatide includes muscle as well as fat. Preserving lean mass protects your metabolic rate, which materially affects how hard maintenance is afterwards.
Both drive appetite dysregulation hard. Going into a transition already sleep-deprived and stressed makes everything about it more difficult.
There will be one. Deciding in advance what you do when it arrives is very different from improvising while it's happening.
This is a common point at which people go looking for help, and it doesn't change what's possible. The work is the same — rebuild the structure that manages appetite. Starting from here is harder than starting before you stopped, but it is entirely doable, and it is not starting from zero: you know a great deal more about your own appetite than you did before.
Perdura is a coaching programme, not a medical service. This guide is general information and not medical advice.
Never stop, start or change the dose of Mounjaro or any other medication based on something you have read here. Those decisions belong with your prescriber, and we will always ask you to keep them involved. If you are considering coming off, speak to them first — including about whether tapering is appropriate for you.
Mounjaro is a prescription-only medicine. For clinical information about it, see the NHS page on tirzepatide.
Perdura is a structured twelve-week programme for people coming off GLP-1 medication. It works whether you're currently taking it, tapering, or have already stopped — though the earlier you start, the more of the transition you get to prepare for rather than react to.